Ausgabe 2/2013
Inhalt (23 Artikel)
Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
Sanjay Kalra
Adherence to Therapies in Patients with Type 2 Diabetes
Luis-Emilio García-Pérez, María Álvarez, Tatiana Dilla, Vicente Gil-Guillén, Domingo Orozco-Beltrán
Incretin-Based Therapies: Focus on Effects Beyond Glycemic Control Alone
Jaime A. Davidson
Management of Type 2 Diabetes Mellitus in Older Patients: Current and Emerging Treatment Options
Etie Moghissi
Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment
Anja Schweizer, Sylvie Dejager
Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures
Joel M. Neutel, Cathy Zhao, Chetan S. Karyekar
Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE
Chantal Mathieu, Claes-Göran Östenson, Stephan Matthaei, Matthew Reaney, Thure Krarup, Bruno Guerci, Jacek Kiljański, Carole Salaun-Martin, Hélène Sapin, Michael Theodorakis
Safety and Effectiveness of Switching from a Basal-only to Biphasic Insulin Aspart 30 Insulin Regimen
Jihad Haddad, Mohsen Khoshniatnikoo, Youcef Benabbas, Serdar Guler, Vinay Prusty, Pradana Soewondo
Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis
Hiroyuki Ito, Mizuo Mifune, Eriko Matsuyama, Masahide Furusho, Takashi Omoto, Masahiro Shinozaki, Shinya Nishio, Shinichi Antoku, Mariko Abe, Michiko Togane, Shoji Koga, Tsutomu Sanaka
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Tim Heise, Leo Seman, Sreeraj Macha, Peter Jones, Alexandra Marquart, Sabine Pinnetti, Hans J. Woerle, Klaus Dugi
Safety and Effectiveness of Biphasic Insulin Aspart 30 in Different Age-Groups: A1chieve Sub-Analysis
Mohammad Ebrahim Khamseh, Jihad Haddad, Wenying Yang, Alexey Zilov, Ole Molskov Bech, Mohammad Imtiaz Hasan
Annual Medical Costs of Swedish Patients with Type 2 Diabetes Before and After Insulin Initiation
Christin Bexelius, Johan Lundberg, Xuan Wang, Jenny Berg, Hans Hjelm
Initial Management of Severe Hyperglycemia in Patients with Type 2 Diabetes: an Observational Study
William M. King IV, Michael T. McDermott, Jennifer M. Trujillo
Experience with Vildagliptin in Type 2 Diabetic Patients Fasting During Ramadan in France: Insights from the VERDI Study
Serge Halimi, Marc Levy, Dominique Huet, Stéphane Quéré, Sylvie Dejager
Clinical Experience with Insulin Detemir in Patients with Type 2 Diabetes from the Near East Countries
Akram Echtay, Anat Tsur, Mohammad I. Hasan, M. Omar Abu-Hijleh, Nidal Al Khatib, Emile Andari, Paola Atallah, Saleem Qureshi, Jamal Zafar, Levent Sandalci, Asude Ademogulları, Jihad Haddad, Bracha Dagan
Efficacy of Initial Basal-Supported Oral Therapy with Sitagliptin in Untreated Type 2 Diabetes
Keiji Yoshioka
Incretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin
Pedro Mezquita Raya, Antonio Pérez, Antonio Ramírez de Arellano, Teresa Briones, Barnaby Hunt, William J. Valentine
Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
Daniel A. Tatosian, Ying Guo, Andrea K. Schaeffer, Natalia Gaibu, Serghei Popa, Aubrey Stoch, Ronald B. Langdon, Eunkyung A. Kauh
Physician Preferences for Extra-Glycemic Effects of Type 2 Diabetes Treatments
Christine Poulos, Juan Marcos González, Lauren J. Lee, Kristin S. Boye, F. Reed Johnson, Jay P. Bae, Mark A. Deeg
Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
Yoshiki Kusunoki, Tomoyuki Katsuno, Kana Miyakoshi, Takashi Ikawa, Rie Nakae, Fumihiro Ochi, Masaru Tokuda, Takafumi Akagami, Kazuki Murai, Masayuki Miuchi, Tomoya Hamaguchi, Jun-ichiro Miyagawa, Mitsuyoshi Namba
Age-Specific Effectiveness and Safety of Newly Initiated Insulin Therapy in Japanese Patients with Uncontrolled Diabetes
Takayoshi Shiga, Hirohide Yokokawa, Yoshinobu Taneda, Eiichiro Sugihara, Mayumi Meijyo, Kazunori Mitsuhashi, Teruhiko Hisaoka, Hiroshi Isonuma
Erratum to: Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
Samuel S. Engel, Elizabeth Round, Gregory T. Golm, Keith D. Kaufman, Barry J. Goldstein